Everolimus after Hepatic Arterial Embolisation Therapy of Metastases from Gastrointestinal Neuroendocrine Tumours: The FFCD 1104-EVACEL-GTE Phase II Study
SSRN Electronic Journal2018
Thomas Walter, Côme Lepage, R. Coriat, Elodie Barbier, G Cadiot, F. X. Caroli Bosc, T. Aparicio, Karine Bouhier Leporrier, O. Hentic Dhome, F. Gay, Anne-Claire Dupont-Gossart, M. Duluc, Céline Lepère, Thierry Lecomte, Denis Smith, C. Petorin, F. Di Fiore, François Ghiringhelli, J. L. Legoux, Rosine Guimbaud, Éric Baudin, C. Lombard Bohas, Thierry de Baère
Related Papers
- → A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors(2018)46 cited
- → Emerging use of everolimus in the treatment of neuroendocrine tumors(2017)20 cited
- Synergistic effect of combined treatment with 177Lu-DOTATATE and Everolimus in neuroendocrine tumors as monitored by 18F-FDG-PET: Studies in human neuroendocrine xenografts(2012)
- → Data from A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors(2023)
- → Data from A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors(2023)